financetom
Business
financetom
/
Business
/
Ensign Energy beats Q3 revenue estimates, revises debt reduction target to H1 2026
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ensign Energy beats Q3 revenue estimates, revises debt reduction target to H1 2026
Nov 7, 2025 2:24 AM

Overview

* Ensign Energy Q3 revenue beats analyst expectations despite a 5% yr/yr decline

* Adjusted EBITDA for Q3 2025 falls 17% yr/yr

* Company records Q3 net loss of C$3.3 mln, down from net income last year

Outlook

* Ensign revises debt reduction target to first half of 2026 due to industry conditions

* Company budgets 2025 maintenance capital expenditures at C$154.0 mln

* Geopolitical tensions and OPEC+ changes add uncertainty to oil and gas markets

Result Drivers

* GEOPOLITICAL TENSIONS - Co cites geopolitical tensions and global trade uncertainties as factors affecting results

* U.S. OPERATIONS IMPACT - U.S. operations affected by customer capital discipline and rig reactivation costs

* INTERNATIONAL DECLINE - International revenue decreased due to rigs coming off contract

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat C$411.20 C$404.50

Revenue mln mln (4

Analysts

)

Q3 EPS -C$0.02

Q3 Net -C$3.30

Income mln

Q3 C$98.60

Adjusted mln

EBITDA

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the oil & gas drilling peer group is "buy."

* Wall Street's median 12-month price target for Ensign Energy Services Inc ( ESVIF ) is C$3.00, about 19.7% above its November 6 closing price of C$2.41

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
SpringWorks Therapeutics Insider Sold Shares Worth $2,558,237, According to a Recent SEC Filing
SpringWorks Therapeutics Insider Sold Shares Worth $2,558,237, According to a Recent SEC Filing
Feb 13, 2025
04:12 AM EST, 02/13/2025 (MT Newswires) -- Saqib Islam, Director, Chief Executive Officer, on February 10, 2025, sold 48,000 shares in SpringWorks Therapeutics ( SWTX ) for $2,558,237. Following the Form 4 filing with the SEC, Islam has control over a total of 1,002,502 common shares of the company, with 1,002,502 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1773427/000110465925012363/xslF345X05/tm256428-3_4seq1.xml ...
Ascendis Pharma Allocates $25 Million for Share Repurchases, Net Settlement of RSUs
Ascendis Pharma Allocates $25 Million for Share Repurchases, Net Settlement of RSUs
Feb 13, 2025
04:09 AM EST, 02/13/2025 (MT Newswires) -- Ascendis Pharma ( ASND ) said late Wednesday its board has allocated $25 million to fund a share buyback program and the net settlement of certain restricted stock units, or RSUs. The buyback program authorizes the repurchase from time to time of up to about $18.3 million of American depositary shares. The company...
Boston Scientific Insider Sold Shares Worth $1,265,815, According to a Recent SEC Filing
Boston Scientific Insider Sold Shares Worth $1,265,815, According to a Recent SEC Filing
Feb 13, 2025
04:15 AM EST, 02/13/2025 (MT Newswires) -- Edward J Ludwig, Director, on February 11, 2025, sold 12,000 shares in Boston Scientific ( BSX ) for $1,265,815. Following the Form 4 filing with the SEC, Ludwig has control over a total of 24,398 common shares of the company, with 24,398 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/885725/000122520825001594/xslF345X05/doc4.xml ...
SpringWorks Therapeutics Insider Sold Shares Worth $1,617,329, According to a Recent SEC Filing
SpringWorks Therapeutics Insider Sold Shares Worth $1,617,329, According to a Recent SEC Filing
Feb 13, 2025
04:11 AM EST, 02/13/2025 (MT Newswires) -- Daniel Pichl, Chief People Officer, on February 10, 2025, sold 29,750 shares in SpringWorks Therapeutics ( SWTX ) for $1,617,329. Following the Form 4 filing with the SEC, Pichl has control over a total of 50,762 common shares of the company, with 50,762 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1773427/000110465925012365/xslF345X05/tm256428-5_4seq1.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved